Condition: B-Cell Non-Hodgkin's Lymphoma (NHL) · Lymphoma, Non-Hodgkins · Lymphomas Non-Hodgkin's B-Cell · Sponsor: Estrella Biopharma, Inc.
This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase.
This description comes directly from the study's public registry record.
Teresa Klask, MBA · 925-949-9314 · teresa.klask@eurekainc.com
Pei Wang, PhD · 510-654-7045 · pei.wang@eurekainc.com
Always discuss trial participation with your own doctor first.
| University of California, Davis | Sacramento, California, United States | Recruiting |
| Baylor Scott & White Research Institute, Texas Oncology | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06343311